All News

UNITE HERE, a labor union representing 270,000 workers people across Canada and the US, is has questioned pharma’s connections to the influential and highly visible American Heart Association (AHA). Casey McDonald reports.

The issue of drug price controls in public prescription programs has long been a point of contention. But today, writes Tom Norton, as several historical and contemporary factors continue to line up, we may be on a pathway to changing that.

A recent poll reported that most Americans think drug prices are unreasonably high, but that 76% of Republicans prefer market competition over government regulation to lower prices. Stephen Littlejohn imagines what Donald Trump would say on the matter.

August 11, 2015.

An internal audit of payment practices in Eastern Europe has revealed payments for elaborate travel for government health authorities and state-employed physicians in exchange for approval and prescription of your products. What is the first thing you should do? Lawyer Mara Senn offers some advice.

Amgen and Sandoz received a decision from the U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday. PharmExec spoke with legal and biosimilar experts for their initial reactions.

July 9, 2015.

Not so long ago, pharmaceutical brand managers considered drug packaging an afterthought. Today, packaging not only matters, it is quickly becoming one of the most important considerations in the growth and success of any drug product. Manufacturers now consider innovative, smart packaging that pleases patients in their new roles as consumers, and encourages brand loyalty to be a game changer in an increasingly competitive and crowded biopharmaceutical market.

Sponsored contentThe term “patient centric” has become an almost catch-all term. Cheryl Lubbert looks at the broad range of its application. A review of how patient centricity is being applied shows that it is all of these things and more. A look at just a few different uses of the term shows the broad range of its application:

Casey McDonald presents some highlights from a blustery few days in Chicago, with immunotherapy and cost, predictably taking center stage.

Intellectual property lawyers estimate biosimilar litigation will swell as early as 2018.

Watching the latest volleys fly in the ongoing specialty drug pricing wars, Tom Norton wonders: Is it possible that all involved couldn’t just step back and take a breath?

Tactics pharma leaders can implement to stem the continued global threat of counterfeit drugs.

Pricing and Sovaldi couldn’t avoid mention at this week’s World Medical Innovation Forum put on by Partners Healthcare in Boston. The meeting highlighted multiple issues in neuroscience but also touched on hot buttons across the industry.

Is it time to view cell therapy companies differently on Wall Street-even distinct from biotech?

Does patient choice matter to antitrust enforcers?

In reaction to AbbVie’s massive acquisition of Pharmacyclics, investors who were caught unprepared are looking for ways they could have predicted the deal. Casey McDonald looks at the reaction on Twitter.

The cholesterol-fighting market is back with a vengeance; plenty of complications in store

How pharma can finally put true meaning behind its juiced-up jargon and turn the bluster into reality.

Two commercial marketing experts discuss how this mission critical function must change to stay relevant in bringing new therapies to the patients who need them.

The Army General who led the Iraqi 'surge’ campaign cites nine lessons that pharma leaders can apply in today’s come-from-behind struggle for market share.

As we wrap up the week in San Francisco, here’s PharmExec's brief rundown of some of the top tweets of the week from JP Morgan and Biotech Showcase.

Click on the links below to download Pharmaceutical Executive's media kits.

AmerisourceBergen, big Pharma’s top distribution partner, looks to build on its US success in healthcare delivery to create a global service mix focused on knowledge transfer, scale and reach, and partnered innovation.

Patient access to critical experimental medicines continues to grab public attention, as states enact “Right-to-Try” laws and Congress eyes establishing a national policy to provide not-yet-approved therapies to terminally ill patients